Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers.
about
Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblastsMolecular cloning and characterization of EndoGlyx-1, an EMILIN-like multisubunit glycoprotein of vascular endotheliumNeuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-αMolecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancersProcaryotic expression of single-chain variable-fragment (scFv) antibodies: secretion in L-form cells of Proteus mirabilis leads to active product and overcomes the limitations of periplasmic expression in Escherichia coliIdentification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancerHuman tenascin: primary structure, pre-mRNA splicing patterns and localization of the epitopes recognized by two monoclonal antibodiesWhole Tumor Antigen Vaccines: Where Are We?Animal models and the tumor microenvironment: studies of tumor-host symbiosisThe pharmacological landscape and therapeutic potential of serine hydrolasesRationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategyEndothelial to mesenchymal transition is common in atherosclerotic lesions and is associated with plaque instabilityThe application of the fibroblast activation protein α-targeted immunotherapy strategyFibroblast activation protein α in tumor microenvironment: recent progression and implications (review)Identification of an alternatively spliced seprase mRNA that encodes a novel intracellular isoformIdentification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidaseRegulation of fibroblast migration on collagenous matrix by a cell surface peptidase complexIntrahepatic expression of the hepatic stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infectionStructural and kinetic analysis of the substrate specificity of human fibroblast activation protein alphaPopulation pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patientsFAPalpha, a surface peptidase expressed during wound healing, is a tumor suppressorIdentification of novel vascular markers through gene expression profiling of tumor-derived endothelium.Phase I trial of PT-100 (PT-100), a cytokine-inducing small molecule, following chemotherapy for solid tumor malignancy.Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity.Stromal influences on breast cancer cell growth.Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites.Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma.Transcriptional profiling differences for articular cartilage and repair tissue in equine joint surface lesions.Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity.Tumoral immune suppression by macrophages expressing fibroblast activation protein-α and heme oxygenase-1.Pediatric phase I trial design using maximum target inhibition as the primary endpointCancer-associated fibroblasts are positively correlated with metastatic potential of human gastric cancers.Targeted disruption of mouse fibroblast activation protein.Fibroblast heterogeneity in the cancer wound.Cancer associated fibroblasts (CAFs) in tumor microenvironment.Fibroblast activation protein protects bortezomib-induced apoptosis in multiple myeloma cells through β-catenin signaling pathwayTranscriptional regulation of seprase in invasive melanoma cells by transforming growth factor-β signaling.Fibroblastic reticular cells of the lymph node are required for retention of resting but not activated CD8+ T cells.Clinical Implications of Marker Expression of Carcinoma-Associated Fibroblasts (CAFs) in Patients with Epithelial Ovarian Carcinoma After Treatment with Neoadjuvant Chemotherapy.Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia.
P2860
Q22010913-4271AE1E-610A-49A1-B0A5-9F6D90D3E1EAQ24291693-73734675-47C1-471D-A37D-1C3C18F3E9FBQ24292941-F7B9BC89-6BF0-49BD-941A-43B5C33BE98AQ24319154-AD590BE9-267C-4AA3-BF86-69937F966136Q24550594-7C27EE8E-9357-4D28-B28D-824B57C7BE2DQ24563227-73E9E9AE-9A07-4820-8005-F3FB84D21B52Q24633292-E78F6CB1-2EAC-4A08-9420-668DA2527331Q26783866-C5436C0E-EFF3-4489-8370-DC61EBECA563Q26853538-56C30CC3-C3F4-43D3-8E8F-5111624689D9Q26995817-EE7D4A97-F7A4-4890-9350-2591DBFC2336Q27004215-B2A2A0B8-D20B-47BB-8960-718F24A3B067Q27313607-25097A3C-D5AA-45EF-BC36-DA5802460E30Q28073437-6CAA32C0-9AB7-471C-84C3-55CEE312D69BQ28082504-DBBDD0A3-F869-49BB-B1E3-6292B70F0675Q28143125-EBE18258-07E8-44C0-9247-933122F5DE7AQ28147264-D2071B4D-C64B-4C3D-B2F7-5443B8F30406Q28218749-95CCE4F7-51B7-41A5-9869-65FB0E1EA61BQ28218916-4E7C4090-4929-4262-9491-72859F51ACFBQ28243456-1A3C93ED-BBA3-4245-8512-288EC46B903DQ28361034-CE071437-9747-4BAE-9ECD-C6B240DD5FF1Q28513202-E0FA6C7E-B2FF-4B0F-809D-9BA1715C43C9Q30843102-555A2E1A-BA2A-49AB-881F-69EA44E58AD5Q33154279-03C65225-17E3-4D8D-BDA9-D40E25A60454Q33231553-E89677BE-BEB8-4C19-B281-97A55ACA2E4AQ33276533-3B93B2DF-B5C4-4ACC-88C2-CAA0922FD342Q33311561-7530C316-667F-41C5-8167-FFA5B827EF05Q33488712-DC3F95BF-50FC-49EF-BD52-FF668B9E801CQ33502875-BA04B6BD-2616-4124-81A9-85D65D599789Q33555573-5D83FDF4-6ECF-4217-806C-C2B57EE7907BQ33557006-F13F7828-A0CF-4683-8566-CC8A4A86642FQ33915053-5240631B-E7E9-4421-9129-065A5C498E33Q33942225-8242D7CC-89A1-4A42-B12C-5BC5F9DD063DQ33961797-4D8D6E0B-9DA8-4C97-BC6C-236B105A7778Q33964324-E336CDFD-DF85-4419-BB32-03D1FE0AA729Q33999773-D152B123-1A3A-4363-8932-BFF8A516D9E2Q34036138-71DE88BE-E539-4AD2-950C-5328CC826D25Q34075875-F4822B94-D3B7-4716-9FAD-DEDCB00E8B33Q34082904-F7929154-DBF8-4CF0-8C97-12698EDC74B2Q34115941-C0A452DD-9D18-4A44-9759-AC1384E04E74Q34347056-A143DDC5-0819-4220-BE1B-C58DF1D1F3D6
P2860
Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers.
description
1990 nî lūn-bûn
@nan
1990 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年学术文章
@wuu
1990年学术文章
@zh-cn
1990年学术文章
@zh-hans
1990年学术文章
@zh-my
1990年学术文章
@zh-sg
1990年學術文章
@yue
name
Cell surface glycoprotein of r ...... t in human epithelial cancers.
@ast
Cell surface glycoprotein of r ...... t in human epithelial cancers.
@en
type
label
Cell surface glycoprotein of r ...... t in human epithelial cancers.
@ast
Cell surface glycoprotein of r ...... t in human epithelial cancers.
@en
prefLabel
Cell surface glycoprotein of r ...... t in human epithelial cancers.
@ast
Cell surface glycoprotein of r ...... t in human epithelial cancers.
@en
P2093
P2860
P356
P1476
Cell surface glycoprotein of r ...... t in human epithelial cancers.
@en
P2093
P Garin-Chesa
W J Rettig
P2860
P304
P356
10.1073/PNAS.87.18.7235
P407
P577
1990-09-01T00:00:00Z